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STUDY PROTOCOL Open Access
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effectiveness of internet-delivered
interventions for depression and anxiety
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Abstract
Background: Depression and anxiety are common mental health disorders worldwide. The UK’s Improving Access
to Psychological Therapies (IAPT) programme is part of the National Health Service (NHS) designed to provide a
stepped care approach to treating people with anxiety and depressive disorders. Cognitive Behavioural Therapy
(CBT) is widely used, with computerised and internet-delivered cognitive behavioural therapy (cCBT and iCBT,
respectively) being a suitable IAPT approved treatment alternative for step 2, low- intensity treatment. iCBT has
accumulated a large empirical base for treating depression and anxiety disorders. However, the cost-effectiveness
and impact of these interventions in the longer-term is not routinely assessed by IAPT services. The current study
aims to evaluate the clinical and cost-effectiveness of internet-delivered interventions for symptoms of depression
and anxiety disorders in IAPT.
Methods: The study is a parallel-groups, randomised controlled trial examining the effectiveness and cost-
effectiveness of iCBT interventions for depression and anxiety disorders, against a waitlist control group. The
iCBT treatments are of 8 weeks duration and will be supported by regular post-session feedback by
Psychological Wellbeing Practitioners. Assessments will be conducted at baseline, during, and at the end of
the 8-week treatment and at 3, 6, 9, and 12-month follow-up. A diagnostic interview will be employed at
baseline and 3-month follow-up. Participants in the waitlist control group will complete measures at baseline
and week 8, at which point they will receive access to the treatment. All adult users of the Berkshire NHS
Trust IAPT Talking Therapies Step 2 services will be approached to participate and measured against set
eligibility criteria. Primary outcome measures will assess anxiety and depressive symptoms using the GAD-7
and PHQ-9, respectively. Secondary outcome measures will allow for the evaluation of long-term outcomes,
mediators and moderators of outcome, and cost-effectiveness of treatment. Analysis will be conducted on a
per protocol and intention-to-treat basis.
(Continued on next page)
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Discussion: This study seeks to evaluate the immediate and longer-term impact, as well as the cost effectiveness of
internet-delivered interventions for depression and anxiety. This study will contribute to the already established literature
on internet-delivered interventions worldwide. The study has the potential to show how iCBT can enhance service
provision, and the findings will likely be generalisable to other health services.
Trial registration: Current Controlled Trials ISRCTN ISRCTN91967124. DOI: https://doi.org/10.1186/ISRCTN91967124. Web:
http://www.isrctn.com/ISRCTN91967124.
Clinicaltrials.gov: NCT03188575. Trial registration date: June 8, 2017 (prospectively registered).
Keywords: Depression, Anxiety, IAPT, iCBT, RCT, Internet-delivered
Background
According to the Global Burden of Disease (GBD) study,
depression and anxiety disorders contribute the highest
degree of disability amongst all mental and substance
abuse disorders [1]. Both anxiety and depressive disor-
ders contribute to increased societal costs through
higher health care utilisation [2, 3], as well as absentee-
ism from work [4]. In Europe, the total cost of mood
disorders in 2010 was €113.4 billion, comprising direct
health care costs and indirect costs including unemploy-
ment, sickness benefit, lost productivity, and early retire-
ment [5]. In England, approximately 1 in 6 adults have a
common mental disorder [6], and mental health disor-
ders / difficulties have been estimated to represent 23%
of the total cause of disability, higher than other condi-
tions such as cancer and CHD [7].
Treatment of depression and anxiety
Psychological therapies have been demonstrated to be
equally as effective as anti-depressant medication [8] and
a recent meta-analysis of 34 studies shows a consistent
patient preference for psychological vs. pharmacological
treatment [9]. Furthermore, psychological therapies such
as Cognitive Behavioural Therapy (CBT) have been shown
to be clinically and cost effective [10, 11] and has demon-
strated effectiveness in treating, maintaining progress, and
preventing relapse in both depression and anxiety disor-
ders [12–15].
Psychiatric disorders are seldom the principal reason
for GP visits, and yet in one primary care study, depres-
sion was encountered in upwards of 31% of consulta-
tions, with anxiety detected in approximately 19% of
consultations [16]. However, once identified, a multitude
of factors prevent individuals from accessing evidence-
based psychological interventions, including long waiting
lists and a shortage of trained professionals [17]. A num-
ber of studies have investigated how depression and anx-
iety disorder treatment in primary and specialised care
settings can be improved [18] by means of ‘collaborative
care’ [19], ‘disease management’ approaches, and ‘stepped
care’ initiatives [20]. Within stepped care, professionally
guided low-intensity self-help interventions have become
an attractive evidence-based alternative. Low-intensity
interventions refer to those that require less time with a
specialist therapist and include bibliotherapy, guided
self-help, and internet-delivered CBT interventions [21].
Improving access to psychological therapies
The Improving Access to Psychological Therapies (IAPT)
programme involves a five-step approach to psychological
care for people with depression and anxiety within the
National Health Service (NHS) mental health services
[22]. Stepped care models match treatment intensity to
client needs by providing the least intrusive and most
effective intervention for the client upon entering services.
This allows for the effective management of resources,
thus increasing access [23].
Step 2 of IAPT allows access to evidence-based treat-
ments by delivering low-intensity psychological support
to patients presenting with mild to moderate symptoms
of depression and anxiety. These interventions are often
delivered by Psychological Wellbeing Practitioners
(PWPs), who are predominantly graduate psychologists
with further training in delivering low-intensity CBT-
based interventions [22].
A key aspect of the success of the IAPT model is its
ability to report on outcomes. All services have a
requirement to collect data on patients, access times,
waiting times, dropout, treatment type, clinical out-
comes, employment status, and work and social adjust-
ment. Together, these outcomes collectively inform the
success of the IAPT service.
As recommended by the National Institute for Health
and Care Excellence [10, 11], the IAPT programme add-
itionally offers computerised cognitive behavioural ther-
apy (cCBT) as a low-intensity, Step 2 intervention for
individuals presenting with mild to moderate symptoms
of depression and/or anxiety. cCBT and internet-
delivered cognitive behaviour therapy (iCBT) are deliv-
ered by PWPs, whose support is offered by means of
electronic or telephone communication. Digital services
in IAPT have been implemented at step 2 to help over-
come the common barriers to accessing mental health
treatment, such as costs and long waiting lists. There is
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certainly room for significant growth in these much-
needed digital applications in IAPT, as digital use for
treatment purposes is at less than 2% [24].
There is now a substantial body of research that sup-
ports the efficacy of online delivered CBT for depression
and anxiety disorders [25–27] and findings have been
transferred into clinical practice. This presents an oppor-
tunity to examine the effectiveness of iCBT in a natural
setting.
Cost effectiveness of iCBT
Early cost-effectiveness studies suggested that there
could be large public health savings with the use of
cCBT for treating depression and anxiety in mental
health services [28]. In fact, the National Institute for
Health and Care Excellence recommended the use of
computerised CBT interventions partially based on this
data [10, 11].
A recent systematic review of economic evaluations of
internet-delivered interventions for mental health
highlighted that interventions for depression and anxiety
demonstrated cost-effectiveness compared to unguided
interventions, waiting list controls, treatment as usual,
group CBT, and telephone counselling [29]. The authors
also make a call for future studies to firmly establish the
cost-effectiveness of internet-delivered interventions.
Mechanisms of change in iCBT
Understanding the factors that account for therapeutic
changes is a key factor in providing the best patient care
and assists in the pathway toward improving psycho-
logical treatments [30]. Despite the large body of
research on mechanisms of change in traditional CBT,
little has been achieved to date in understanding the
mechanisms that drive change and their relative contri-
bution to outcomes in iCBT [31]. Mechanisms of change
comprise both general and specific factors: general fac-
tors include elements such as the therapeutic alliance,
credibility of treatment, and belief about the potential
of the intervention; specific factors include cognitive or
meta-cognitive mechanisms, such as change in dysfunc-
tional attitudes or repetitive negative thinking styles,
improvement in emotion regulation abilities, cognitive
and behavioural treatment skills usage, and therapist
behaviours [32].
Aims
The overarching aim of the present study is to imple-
ment and evaluate the long-term effectiveness & cost-
effectiveness of internet-delivered interventions for
depression and anxiety disorders within IAPT services.
The specific research questions include the following:
 Are the SilverCloud Space from Depression and
Space from Anxiety internet-delivered interventions
in IAPT effective in treating depression and anxiety
disorders, and maintaining outcomes at follow-up,
compared to waiting-list groups?
 Are the SilverCloud Space from Depression and
Space from Anxiety internet-delivered interventions
cost-effective in treating depression and anxiety
disorders in IAPT?
 Are mediators/mechanisms of change and
maintenance associated with both post-treatment
and long-term effectiveness of internet-delivered
interventions for depression and anxiety?
We hypothesize that: a) the iCBT interventions will be
more effective than the waiting-list group in treating de-
pression and anxiety disorders; b) the iCBT interven-
tions will be cost-effective compared to the waiting-list
group in treating depression and anxiety; c) we expect
that mediators/ mechanisms of change including, repeti-
tive negative thinking styles, emotion regulation skills,
therapeutic alliance, credibility and expectancy in iCBT,
CBT skills usage and therapist behaviours will be identi-
fied as positively impacting post-treatment outcomes
and maintenance of gains in iCBT.
Methods
Study setting
Study setting
This naturalistic study will be conducted within Berkshire
Healthcare NHS Foundation Trust through Talking Ther-
apies, an NHS IAPT provider, that serves a population of
900,000 across 7 Clinical Commissioning Groups (CCGs),
all of which are demographically and economically diverse,
ranging from rural West Berkshire to urban commuter
towns close to London. Talking Therapies aims to provide
an easily accessible and clinically effective service for those
within the community who suffer from anxiety and depres-
sive disorders. These objectives were met in the last year by
providing a stepped care model of mental health services to
over 11,000 individuals. Those wishing to access the service
can do so through self-referral, GP referral, or referral from
allied services. If suitable, clients are offered treatment ei-
ther at Step 2 or Step 3 based on their need. Step 2 services
include low-intensity CBT-based treatments such as guided
self-help, iCBT and group treatment, supported by trained
psychological wellbeing practitioners (PWP). Step 3 services
include high-intensity face-to-face CBT and counselling in-
terventions, delivered by a variety of counsellors, CBT ther-
apists and psychologists.
Trial design
A parallel-groups, randomised controlled trial design
will be used to examine the effectiveness and cost-
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effectiveness of internet-delivered interventions for de-
pression and anxiety disorders against a waiting list con-
trol group. Based on the primary diagnosis obtained
from the Mini International Neuropsychiatric Interview
7.0.2 (M.I.N.I), participants will be randomised into one
of two groups: one for depression and another for
anxiety.
Randomisation will follow a 2:1 ratio. For ethical
reasons, participants in the control group will receive
access to the internet intervention after the waiting
list period (8 weeks). The study will be conducted fol-
lowing the CONSORT statement [33], the CONSORT
extension for web-based interventions (CONSORT-
EHEALTH) [34] and the SPIRIT guidelines (Standard
Protocol Items: Recommendations for Interventional
Trials) [35]. The SPIRIT checklist can be found in
Additional file 1. The study protocol, information on
the study, informed consent, and trial related docu-
ments have been submitted and approved by the
NHS England Research Ethics Committee [REC Refer-
ence: 17/NW/0311]. The study flowchart is shown in
Fig. 1.
Sample size
Sample size was determined separately for primary pre-
sentations of anxiety disorders and depression for the
trial. Using the software program G-power [36] and
based on a moderate between group effect size of d = 0.5
with a power of 80%, an alpha error of 0.05, and a 2:1
randomisation procedure into immediate treatment and
a corresponding waiting list control group. This calcula-
tion returned a total sample of 144 participants in the
depression arm (96 in the treatment group and 48 in the
WL group) and the same for anxiety, leading to a total
of 288 participants. To ameliorate against attrition, a
25% uplift was added, resulting a total sample size of
360. Therefore, this number translates to a ratio of n =
120 in the treatment group and a corresponding n = 60
Fig. 1 Participant flow – CONSORT
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in the control group for depression, and the same ratio
for anxiety. The 2:1 randomisation procedure was imple-
mented to reduce the likelihood of having many people
waiting for treatment after presenting to the IAPT
service.
Eligibility criteria
Patient eligibility All adult users of the Berkshire NHS
Trust IAPT Talking Therapies Step 2 services will be eli-
gible to participate. Upon screening participants, the in-
clusion and exclusion criteria illustrated in Table 1 will
be applied. Suitability for an internet intervention is
assessed by the PWP based on the willingness of the
participants to engage on the iCBT intervention, pres-
ence of low to moderate levels of anxiety and depression,
no suicidal or self-harm risk, and having internet access.
Clinician eligibility
All Psychological Wellbeing Practitioners (PWP), who
give clinical support to trial participants, will be eligible
to participate in the research that will explore the thera-
peutic alliance online and the use of therapist behaviours
and their relationship to outcomes. PWPs will have re-
ceived training in the use of the iCBT intervention, the
content of the programmes, as well as in delivering feed-
back when inducted into the service. In addition, all
Case Managers providing supervision to clinical sup-
porters of trial participants will be invited to take part in
the research and complete the fidelity checklist, which
assesses the congruence between the PWP’s written re-
views of the clients and the module content they are
completing.
Recruitment
Client recruitment
Recruitment will begin in June 2017 and will continue
for 9 months until the numbers are reached or exceeded.
Given that prevalence of anxiety disorders is higher than
depression, it might be the case that the numbers on the
anxiety arm will be reached before the depression arm.
If necessary, recruitment on the anxiety arm will be
stopped, but patients with primary diagnosis of a specific
anxiety disorder will be still offered treatment.
Regarding the recruitment process, firstly, individuals
will be given an initial assessment by phone with a
Psychological Wellbeing Practitioner (PWP) clinician at
Berkshire IAPT service. The assessment will determine if
an individual meets the eligibility criteria, and an initial
indication of depression, anxiety, or comorbid depres-
sion and anxiety will be advised by the PWP. The PWP
will then describe the trial and invite the client to
participate. Those interested will be assigned a further
telephone appointment, to complete a structured clinical
interview, the Mini-International Neuropsychiatric Inter-
view (M.I.N.I.) [37]. They will also receive an email with
information detailing the study and a link to give con-
sent by means of a digital signature. Upon giving
consent, participants will complete the primary and sec-
ondary outcomes for the study online (described below).
During the M.I.N.I. appointment, the PWP will reiterate
details of the research and the programme, describing
what is involved and the importance of their participa-
tion in the trial. Participants will be allocated to the de-
pression or anxiety arm based on the outcome of the
M.I.N.I., and then randomized to the treatment or the
waiting-list group. They will be informed of the outcome
of randomisation during this appointment. Participants
will then receive an email confirming whether they are
in the immediate treatment group or waiting list group,
and how to proceed. All participants will be informed
they are free to withdraw if they no longer wish to take
part in the trial. In this case, they will be removed from
the trial and they will be offered treatment as usual.
Risk management
At assessment, clients are assessed for risk in line
with routine clinical practice. This includes an assess-
ment of whether patients can maintain their safety
whilst on the waiting list. Those who exceed a clinic-
ally determined cut-off for “low-risk” in terms of sui-
cide and/or self-harm on the screening questions will
not be eligible to participate in the study and will be
referred for additional support (i.e. thoughts of sui-
cide/self-harm may be present but with no active
plans, a low level of intentions to act on these
thoughts with identified protective factors). Integrated
risk measures in the SilverCloud programme allow for
monitoring by supporters of any changes in risk for
patients throughout the programme. For example, if
the patient scores above > 2 on the suicide and self-
harm item of the PHQ-9, the user will be prompted
to complete 3 qualifying questions in relation to
Table 1 Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
Minimum age of 18 years Suicidal intent/ideation: score > 2 on
PHQ-9 question 9
A score of ≥9 on PHQ-9 and/or
a score of ≥8 on GAD-7
Psychotic illness
Suitable for an internet-delivered
intervention (iCBT)
Currently in psychological
treatment for depression and/or
anxiety
Alcohol or drug misuse
Previous diagnosis of an organic
mental health disorder
Note: PHQ-9 Patient Health Questionnaire-9, GAD-7 Generalised Anxiety
Disorder-7, iCBT internet-delivered cognitive behaviour therapy
Richards et al. BMC Psychiatry  (2018) 18:59 Page 5 of 13
plans, intentions, preparations and protective factors
against suicide and self-harm. If required, an alert will
be sent through to their clinician, which can then be
escalated appropriately within the established clinical
governance structure. It is important to note that Sil-
verCloud will not be presented to patients as a
programme capable of providing crisis support, and this
will be further emphasised through informed consent
and the user contract. Once patients have finished the
supported period of the intervention, their outcomes
on the PHQ-9 and GAD-7 will determine whether they
will be appropriately discharged or referred on for fur-
ther treatment within Berkshire NHS Trust IAPT
service.
Clinician recruitment
All PWP clinicians will be invited to a brief information
session where the trial and the objectives will be fully
described. They will be invited to participate as clinical
supporters for the iCBT (Space from Depression and
Space from Anxiety) interventions, but also as research
participants themselves. As research participants PWPs
will:
1. Electronically sign informed consent
2. Complete STAR-C and therapist behaviours check-
list after each review session with a client
3. Participate in a semi-structured interview post-trial
about their experience of the therapeutic alliance
and their use of therapist behaviours.
Randomisation and blinding
Based on the outcome from the M.I.N.I., PWP’s will estab-
lish a primary diagnosis of depression or anxiety disorder
and allocate participants to the depression or anxiety arm,
respectively. Participants will be randomised using an algo-
rithm performed by a computer scientist and executed in-
dependently of the research team, employing random
permuted blocks using block sizes of 9, and including
stratification within a 2:1 allocation ratio between the treat-
ment group and the waiting list control group. The PWP
who carries out the support and assessment of the patients
cannot be blinded to allocation for practical reasons.
Intervention: SilverCloud platform.
SilverCloud Health are global leaders in the develop-
ment of computerised psychological interventions for
depression, anxiety, stress and comorbid long-term
conditions. Both treatments, depression and anxiety,
are delivered on a Web 2.0 platform using media-rich
interactive content. This platform employs several in-
novative and engaging strategies for improving the user
experience. The programme content is delivered in a
non-linear fashion.
Space from depression
The online intervention ‘Space from Depression’ is a
seven-module online CBT-based intervention for depres-
sion, delivered on a Web 2.0 platform using media-rich
interactive content. Programme content is delivered in a
non-linear fashion. Each module takes roughly 1 h to
complete, and it is recommended one module be com-
pleted per week. The structure and content of the
programme modules follow evidence-based CBT princi-
ples. The treatment is comprised of established cognitive
and behavioural components including self-monitoring,
self-control desensitisation, gradual stimulus control,
thought recording, behavioural activation, cognitive re-
structuring, relaxation training and challenging core be-
liefs. In addition, given the frequent comorbidity of
depression with anxiety symptoms, the platform provides
PWPs with an option to deliver a mixed programme com-
prising the core depression modules delivered alongside a
module about worry management. Each module is struc-
tured to incorporate introductory quizzes, videos, infor-
mational content, interactive activities, as well as
homework suggestions and summaries. In addition, per-
sonal stories and accounts from other users are incorpo-
rated into the presentation of the material. The
intervention follows NICE guidelines for the treatment
of depression and the intervention has been tested
and proved efficacious [10, 11, 38].
Space from anxiety
The online intervention ‘Space from Anxiety’ is a seven-
module online CBT-based intervention for anxiety, de-
livered on a Web 2.0 platform using media-rich inter-
active content. Programme content is delivered in a
non-linear fashion. Each module takes roughly 1 h to
complete, and it is recommended one module be com-
pleted per week. The structure and content of the pro-
gram modules follow established evidence-based
principles of CBT for the treatment of anxiety disor-
ders. The treatment comprises cognitive, emotional,
and behavioural components that include self-
monitoring, relaxation training, cognitive restructuring,
and worry outcome monitoring. The intervention also
delivers customisations to modules based on the differ-
ent anxiety disorder presentations, for example, in so-
cial anxiety the modules include attention control and
the personal stories are of individuals experiencing so-
cial anxiety. The getting started module for the core
anxiety programme introduces the user to the cycle of
anxiety and the emotional, cognitive and behavioural
aspects of anxiety. The goal of the intervention is to
help people with anxiety as a primary disorder manage
their thoughts, emotions and behaviours to help them
alleviate their symptoms. The intervention follows
NICE guidelines for the treatment of anxiety [10, 11].
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Waiting list control group
Participants in the waiting list control group receive no
treatment for the duration of the first 8-weeks. At week
8, waiting-list participants will complete the primary and
secondary outcome measures and begin their treatment
with support from a PWP.
Support during treatment
Each participant will be assigned a PWP clinician who
will monitor participants’ progress throughout the trial.
Once assigned to the active treatment condition the par-
ticipant will receive a message from their PWP clinician
at their first login. This message welcomes them to the
program, highlights aspects of the program, and encour-
ages them in use of the program. Over the course of the
8-week supported intervention, on 6 separate occasions
the PWP will login and review participants progress,
leaving feedback for them and responding to the work
they have completed. The basic share level allows sup-
porters to view users’ goals for the week, key messages
and progress points. If users wish to share more with
their supporter, they can share journal entries. Each sup-
porter will provide post-session feedback of between 10
and 15 min per participant per session, over the eight-
week intervention period.
Supporters will be supervised by case managers, who
are responsible for monitoring fidelity of the PWP to the
content of the specific iCBT intervention. At each super-
vision meeting they will complete a fidelity checklist.
The checklist is an assessment of the congruence
between the content of the PWP’s online reviews and
the CBT module that the client is progressing through.
This will ensure that patients receive the appropriate
evidence-based intervention and that each client receives
a similar standard of intervention, augmenting the re-
producibility of the study. Furthermore, the trial steering
group will meet weekly with PWP managers to audit the
trial conduct, its processes and overall progress.
Measures
M.I.N.I. International neuropsychiatric interview 7.0 (MINI)
[37]
The current version is 7.0 and is based both on the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) and the International Classification of Diseases
(ICD-10) criteria. The interview has been well validated
and the administration of the interview by telephone has
been validated. The Interview schedule will include the
following modules: Module A (Major Depressive
Episode), Module D (Panic Disorder), Module F (Social
Anxiety Disorder), and Module N (Generalized Anxiety
Disorder), in order to establish current depression and
anxiety and specific anxiety presentations. For research
purposes randomisation to either Space from Depression
or Space from Anxiety will be based on the outcome
from the M.I.N.I. In the event where a clear diagnosis is
not available the clinician will decide on the diagnosis
based on the outcome from the M.I.N.I. and clinical
knowledge from the initial assessment (scores on the
PHQ-9, GAD-7).
Primary outcome measures
Patient health Questionnaire-9 (PHQ-9) [39, 40]
The PHQ-9 is a self-report measure of depression that
has been widely used in research and is a regular screen-
ing measure utilised in primary care and hospital set-
tings. The PHQ-9 items reflect the diagnostic criteria for
depression outlined by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition – Text
Revision (DSM–IV–TR) [41]. Summary scores range
from 0 to 27, where larger scores reflect a greater sever-
ity of depressive symptoms. The PHQ-9 has been found
to discriminate well between depressed and non-
depressed individuals using the cut-off total score ≥ 10,
with good sensitivity (88.0%), specificity (88.0%) and reli-
ability (89, 39).
Generalized anxiety Disorder-7 (GAD-7) [42]
GAD-7 comprises 7 items measuring symptoms and se-
verity of anxiety based on the DSM-IV diagnostic cri-
teria for GAD. The GAD-7 has good internal
consistency (α = .92) and good convergent validity with
other anxiety scales [42]. Higher scores indicate greater
severity of symptoms. The GAD-7 has increasingly been
used in large-scale studies as a generic measure of
change in anxiety symptomatology, using a cut-off score
of 8 [43].
Secondary outcome measures
Diagnosis-specific measures
Participants with a principal diagnosis of anxiety and of
specific anxiety including social anxiety, GAD, panic dis-
order or health anxiety will also complete the associated
anxiety disorder specific measure depending on their
main diagnosis.
IAPT phobia scales The IAPT Phobia scales have been
designed with the aim of capturing patients who may
score below the clinical cut-off on the PHQ-9 and GAD-
7 but whose lives may be significantly impaired by the
presence of social anxiety, agoraphobia and specific pho-
bias [44].
Social Phobia Inventory (SPIN) [45] Consisting of 17
self-rated items for social anxiety disorder, this test asks
the user to reflect over the past week and report on their
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experiences as laid out by the inventory, which assesses
the domains of social anxiety disorder (fear, avoidance
and physiological arousal). Scores are then totaled to
produce a value that is representative of symptom sever-
ity on a continuum from none to very severe. Internal
reliability for the SPIN has been placed at α = .95, with α
values for the subscales ranging from .79–.85. [45].
Short Health Anxiety Inventory (HAI) [46] This scale
measures levels of health anxiety, which is characterised
by the misinterpretation of bodily sensations as a serious
illness. The shortened version of the scale has been con-
structed such that it is sensitive to both normal and
severe levels of health anxiety. A meta-analysis of the
inventory has yielded α values between .74–.96 [47].
Panic Disorder Severity Scale-Self Report (PDSS-SR)
[48] This scale measures severity of panic disorder and
is considered a reliable tool in treatment outcome stud-
ies. It consists of seven items rated on a 5-point scale
that ranges from 0 to 4. The items assess panic fre-
quency, distress during panic, panic-focused anticipatory
anxiety, and phobic avoidance of situations, phobic
avoidance of physical sensations, impairment in work
functioning, and impairment in social functioning. The
total sum of the individual scores ranges from 0 to 28,
where higher scores indicate greater severity. A score of
9 or above is indicative of caseness. It has displayed good
psychometric properties [49].
The Penn State Worry Questionnaire (PSWQ) [50]
This questionnaire consists of 16 items and is consid-
ered a valid clinical measure of the worry characteristic
of GAD. Each item is measured on a 5-point Likert scale
(1 – not at all typical of me to 5 – very typical of me)
and a total score ranging between 0 and 80 is calculated
by summing all items. Psychometric evaluations have re-
vealed a high internal consistency (α = 0.86 to 0.95) and
test-retest reliability over four weeks (r = 0.74 to 0.93)
[51]. The measure has also been found to successfully
differentiate between patients with GAD and those with
other anxiety disorders [52].
Functional impairment
Work and Social Adjustment (WSAS) [53] This is a
simple, reliable and valid measure of impaired function-
ing. It is a 5-item self-report measure that provides an
experiential impact of a disorder from the patient’s point
of view. It looks at how the disorder impairs the patient’s
ability to function day to day on five dimensions: work,
social life, home life, private life and close relationships.
Cost effectiveness
EuroQoL Five Dimension Five Level Version (EQ-5D-
5 L) [54] This measure is used to assess a person’s per-
ception of their general health state and obtain a meas-
ure of quality adjusted life years (QALYs). Outcomes can
be benchmarked against UK population norms. It covers
five dimensions: mobility, self-care, usual activity, pain/
discomfort and anxiety/depression, which are rated by
the person on five levels of severity: no problems, slight
problems, moderate problems, severe problems and ex-
treme problems/unable to function within that domain.
Recovering Quality of Life – 10 item version (ReQoL-
10) [55] This recently developed measure is used to
assess a person’s perception of their generalised mental
well-being which is associated with recovering quality of
life. The measure focuses on seven key themes associ-
ated with recovering quality of life: well-being; auton-
omy, control, choice; self-perception; relationships and
belonging; hope; activity; physical health. It is composed
of 10 questions (with one additional question focused
on physical health) rated on a 5-point scale which de-
scribes a persons thoughts, feeling and activities over
the last week.
Client Service Receipt Inventory (CSRI) [56] This col-
lects individuals’ use of health and social care resources.
It comprises questions about health care utilization
including inpatient and outpatient hospital services,
community-based day services, primary and community
care contacts and employment status. This version of
the CSRI is routinely administered at the study site.
Satisfaction with treatment measures
Patient Experience Questionnaire (PEQ) [44] This in-
strument will be used to assess patient experience and
satisfaction. The PEQ contains several quantitative ques-
tions and open-ended questions that are used to assess
participant’s views and satisfaction with service
provision.
Mechanisms of change and maintenance
Scale to Assess Therapeutic Relationship – Patient
version (STAR-P) [57] This scale will be employed to
assess patients’ experiences of the therapeutic relation-
ship online. It will be administered to patients through-
out treatment following each progress review with the
clinician.
Scale to Assess Therapeutic Relationship – Clinical
version (STAR-C) [57] This will be employed to assess
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clinicians’ experiences of the therapeutic relationship on-
line. The measure will be administered each time the
clinician writes a review for their clients.
Positive Beliefs about Rumination Scale – Adapted
Version (PBRS-A) [58] This scale has 9 items that
measure positive beliefs about repetitive negative think-
ing. Participants complete each item using a 4-point
scale, 1 = do not agree to 4 = agree very much. The meas-
ure has good internal reliability (α = .89).
Emotion Regulation Questionnaire (ERQ) [59] The
ERQ is a 10-item scale that assesses individual differ-
ences in the habitual use of two emotion regulation
strategies: cognitive reappraisal and expressive suppres-
sion. Each item is rated on a 7-point scale so that higher
scores indicate higher use of reappraisal/ suppression.
This scale has shown appropriate levels of internal reli-
ability on both subscales, reappraisal and suppression
(0.79 and 0.73, respectively).
Frequency of Actions and Thoughts Scale (FATS)
[60] The FATS is a 12-item scale, designed to assess the
frequency with which CBT-related skills have been used
during the previous week. Each item is measured on a 5-
point scale (0 = not at all, 1 = one or two days; 2 = half
the days; 3 = almost every day; 4 = every day). The FATS
comprises four subscales, indicative of how much the
person engaged in 1) cognitive restructuring, 2) social
interaction, 3) rewarding behaviours and 4) activity
scheduling in the past week; but also gives an overall
score, indicative of overall CBT-related skills usages. Psy-
chometric evaluations suggest high internal consistency
of the total FATS scale (α = 0.86) and acceptable to high
internal consistency of its subscales (α = 0.74 to 0.83).
The FATS has been shown to be sensitive to change dur-
ing iCBT and higher scores on the FATS have been
linked to better treatment outcomes.
Psychological wellbeing practitioner behaviours
checklist A checklist of behaviours based on existing lit-
erature has been developed to assess the behaviours used
by PWPs in their communication with patients. The
checklist is based on known therapist behaviours and
the items have been evaluated by PWPs for relevance. It
will be an optional function within the SilverCloud plat-
form that PWPs will be invited to complete each time
they communicate with their patient.
Expectancy/credibility questionnaire This is a one
question item that assesses the clients level of credibility
with the intervention and is based on the work in this
area [61].
Dropout measure
Finally, a dropout questionnaire will assess participants’
reasons for dropout from treatment. It includes only one
open question asking for details about the specific rea-
sons for dropout.
The study measures and assessment times are sum-
marised in Table 2.
Engagement and usage measures The online system
will collect anonymized descriptive data relating to en-
gagement and usage of the service users with the plat-
form. Data collected will include the number of modules
completed, time spent in the platform, number of activ-
ities completed, number of minutes per log-in, number
of sessions and length of sessions. A session is defined
as an instance where a user logs on to the system. Ses-
sion time will be always an imperfect calculation, as
users may take breaks within a session, without formally
log out of the system. To prevent this overestimation,
periods of more than 30 min without interaction will be
taken as one minute and periods of inactivity longer
than 3 h will start the count on a new session. Use of
different program components will be measured.
Statistical analysis
The effectiveness of the internet-delivered interventions
compared to control will be analysed using the intention
to treat (ITT) approach. Participation levels will be mon-
itored throughout the study and reasons for withdrawal
or non-compliance of study subjects will be recorded to
document bias associated with non-random protocol de-
viations. Any potential imbalances will be reported and
considered fully in interpretation of the trial results.
Missing data will be evaluated for randomness and im-
puted using multiple imputation procedures.
Differences in baseline primary and secondary out-
come measures between treatment groups and waiting
list control groups will be identified using χ2 tests for
categorical variables and ANOVAs or t-tests for continu-
ous variables. Efficacy of treatments over time will be
measured using mixed effects models. To complement
the post-hoc comparisons, the magnitude of change
within and between the groups on the primary and sec-
ondary outcomes measures will be established using
Cohen’s d statistic. Bonferroni corrected p-values will be
reported for multiple comparisons. All statistical ana-
lyses will be conducted in SPSS, SAS and R. Results will
be presented following CONSORT guidelines for report-
ing parallel group randomised trials.
The established IAPT definitions of recovery will be used
in our analysis, where ‘recovery’ is determined by patients
moving from ‘caseness’ at the beginning of the intervention
(i.e. scoring ≥9 on the PHQ-9 or ≥8 on the GAD-7) to
‘non-caseness’ at the end of treatment (thus scoring below
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the cut-off). Two further established measures will be con-
sidered: reliable improvement, where the patient has a sig-
nificant decrease in their PHQ-9 / GAD-7 score upon
completion of their course of treatment; and reliable recov-
ery, where the patient meets the criteria for both recovery
and reliable improvement. Thus, a patient who moves from
caseness to non-caseness, and does so by showing a signifi-
cant decrease in their symptom scores, is said to have a reli-
able recovery [44].
Exploratory analyses, including the use of correlation
and multiple regression, will be conducted to explore
the role that mechanisms of change and maintenance
measures play in the benefits obtained from the inter-
ventions. Moderation and mediation analyses may
include the use of macros for SPSS and/or bootstrapping
for exploring the role that mechanisms of change play
on the outcomes.
Resource-use and subsequent costs will be estimated
over the 12-month time horizon for the intervention
group and for the 8-week waiting list time period for the
control group. Healthcare resource will be valued using
unit costs derived from available data sources [62–66].
For the purpose of the economic evaluation, EQ-5D-
5 L and ReQoL-10 preference-based tariff score values
will be used to elicit the quality adjusted life year
(QALY) using the area under the curve (AUC) method
to account for the collection of this data at multiple time
points between baseline and 12-month follow-up in both
trial-arms. The proposed economic analysis will be con-
ducted for those with anxiety and those with depression
separately and as a whole patient group. All economic
analysis will be performed using Stata version 14 (or an
updated version). Due to the shorter time horizon of the
control groups (8 weeks based on a waiting list
approach) compared to the intervention group
(12 months with outcome assessment at 8 weeks,
6 months, 9 months and 12 months), methodological
work will be carried out to assess the feasibility and un-
certainty around extrapolating outcomes from the 8-
week time period in the control group to a longer time
horizon (e.g. 6-months, 9-months and 12-months) using
survival analysis methods [67]. Cost per QALY analysis
will be carried out over multiple time horizons (e.g. 8-
weeks, 6-months, 9-months and 12-months) to address
Table 2 Study measures and assessment times
Measure Assessment Time of assessment
M.I.N.I. 7.0.2 for DSM-5 Diagnosis BL and 3-FU
PHQ-9 Depression BL, contin, Post-T, FU
GAD-7 Anxiety BL, contin, Post-T, FU
IAPT Phobia Scale Specific Phobia BL, contin, Post-T, FU
WSAS Functioning BL, contin, Post-T, FU
SPIN Social Phobia BL, Post-T, FU
HAI Health anxiety BL, Post-T, FU
PSWQ GAD BL, Post-T, FU
PDSS Panic BL, Post-T, FU
EQ-5D-5 L Health status BL, Post-T, 6-FU, 9-FU, 12-FU
ReQol-10 Recovering quality of life/ mental wellbeing BL, Post-T, 6-FU, 9-FU, 12-FU
CSRI Resource utilisation BL, Post-T, 6-FU
PEQ Patient experience Post-T
STAR-C Therapeutic alliance Throughout treatment, at each review of client
STAR-P Therapeutic alliance Throughout treatment, after each progress review with clinician
PBRS-A Repetitive Negative Thinking BL, week 4, Post-T, 3-FU
ERQ Emotion Regulation BL, Post-T
FATS CBT-related skills usage FU
Therapist behaviours checklist Therapist behaviours During treatment at review of client
Expectancy / credibility Expectancy and credibility with the intervention BL, week 4, Post-T
Dropout questionnaire Reasons for dropout 3-FU
BL Baseline, Post-T Post-Treatment, FU All follow-ups, 3-FU 3-month follow-up, 6-FU 6-month follow-up, contin continuous, PHQ-9 Patient health questionnaire-9,
GAD-7 Generalized anxiety disorder-7, WSAS Work and social adjustment, SPIN Social Phobia Inventory;` HAI Short health anxiety inventory, PDSS Panic disorder se-
verity scale-self report, PSWQ Penn state worry questionnaire, EQ-5D-5 l EuroQol-5 Dimension-5 level, ReQoL-10 Recovering quality of life – 10 item version, CSRI
Client services receipt inventory, PEQ Patient Experience questionnaire, PBSR-A Positive Beliefs about Rumination Scale – Adapted Version, FATS Frequency of
Actions and Thoughts Scale, ERQ Emotion Regulation Questionnaire
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the uncertainty around decision making from using ob-
served data (up to 8 weeks) and extrapolated outcomes
(beyond 8 weeks) for the economic evaluation. Incre-
mental mean point estimates of the difference in cost
and QALYs between trial groups will be used to deter-
mine the incremental cost effectiveness ratio (ICER).
ICER is defined here as the ratio between incremental
costs and incremental effectiveness and the following
formula will be employed:
ICER ¼
Cost active intervention group‐Cost control intervention group
Efectiveness or Utility active intervention group ‐
Efectivenes or Utility control intervention group
:
Statistical bootstrapping will be used to plot the cost-
effectiveness acceptability curves (CEACs) for the purpose
of describing the probability of cost-effectiveness of the
intervention compared to usual care at willingness-to-pay
thresholds normally used by decision makers (i.e. £20,000
per QALY). One-way sensitivity analysis will be used to
describe the uncertainty around these estimates. If the
trial results suggest there is considerable uncertainty
around the cost-effectiveness of the intervention, a simple
economic decision model will be designed to inform an
expected value of information (EVI) analysis. These EVI
results can be used to suggest the upper bound cost of
future research around this area of care.
Discussion
Internet-delivered interventions have evolved in the past
years. Today we have robust technology platforms that
can configure and deliver a range of intervention mod-
ules to meet the needs of the patient. SilverCloud Health
is a global provider of mental health and wellbeing solu-
tions online, and Berkshire NHS trust has been using
SilverCloud interventions which were developed along-
side clinicians at IAPT, and are NICE approved and suit-
able for use at Step 2.
Undertaking the principal aim of this trial will allow
for a robust test of the effectiveness of iCBT in treating
depression and anxiety symptoms, and the maintenance
and cost-effectiveness of these treatment effects in the
long-term. Positive results of these main outcome mea-
sures will allow iCBT to consolidate itself as not only a
valid treatment option, but as an essential component to
the care management pathway offered throughout all
IAPT services. This should support the expansion of
SilverCloud programmes as the leader in the delivery of
digital interventions at Step 2 of IAPT. However, the
relevance of the results will also likely have implications
for the implementation and success of digital interven-
tions for depression and anxiety in health and mental
health care systems worldwide.
Investigating potential mediators and moderators of
change will contribute to our understanding of key
processes in achieving improvement using online-
treatments for anxiety and depression. Mediators and
moderators of iCBT outcomes have been relatively under-
studied, but exploring the roles of constructs such as ru-
mination, emotion regulation, therapeutic alliance and
CBT skills usage will provide insight into clinical change.
This will potentially inform the tailoring of interventions
to best address the needs of the targeted population, ul-
timately leading to the development of more effective
treatments.
The proposed economic analysis will add to the current
empirical literature in regards to evidence of the cost-
effectiveness of internet-based mental health interventions
(i.e. iCBT) and will be an innovative analysis of the Silver-
Cloud iCBT interventions. In a context of health care
provision where resources are already stretched, cost-
effective interventions can only support the delivery of
effective mental health services.
In summary, iCBT interventions are fast becoming a
viable option for patients with depression and anxiety
symptomatology, and are in turn improving the quality
of the services which provide them. They can be benefi-
cial both in costs and time management, and as technol-
ogy moves swiftly so too must research continually and
rapidly inform on the benefits of providing iCBT. This
large-scale trial aims precisely to drive this research for-
ward, thus improving the management and quality of life
of an ever-growing patient population.
Trial status
Recruitment began on 27th June 2017.
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